SCHEMBL7149686

SCHEMBL7149686

COc1ccc2[nH]cc(/C=C3\C(=O)Nc4sccc43)c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.67
NTRK3 Q16288 3/20 0.67
NTRK2 Q16620 3/20 0.67
KDR P35968 3/20 0.67
PRKD3 O94806 2/20 0.67
ABL1 P00519 2/20 0.67
RET P07949 2/20 0.67
PDGFRB P09619 2/20 0.67
LTK P29376 2/20 0.67
FLT3 P36888 2/20 0.67
CSNK1A1 P48729 2/20 0.67
CDK7 P50613 2/20 0.67
MAP2K1 Q02750 2/20 0.67
MST1R Q04912 2/20 0.67
AURKB Q96GD4 2/20 0.67
CLK4 Q9HAZ1 2/20 0.67
ALK Q9UM73 2/20 0.67
MAP2K2 P36507 1/20 0.67
CDK8 P49336 1/20 0.67
SYK P43405 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149696 1.00 NTRK1 (0.67) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL7149690 1.00 NTRK1 (0.67) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL7780481 0.82 NTRK1 (0.83) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL7149051 0.80 NTRK1 (0.64) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL7149059 0.80 NTRK1 (0.64) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL7149055 0.80 NTRK1 (0.64) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL5472269 0.80 NTRK1 (1.00) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL14448937 0.80 NTRK1 (1.00) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL5201532 0.80 NTRK1 (1.00) NTRK1NTRK3NTRK2KDRPRKD3
SCHEMBL7154038 0.79 NTRK1 (0.44) NTRK1NTRK3NTRK2KDRPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6528653-B2 E.g., 4,6-dihydro 4-(heterocyclic ring-methylene)thieno(2,3-b) pyrrolidin-5-one derivatives; tumor necrosis factor ) inhibitors; anticarcinogenic, -proliferative and -arthritic agents; Alzheimer's disease; cardiovascular disorders HOFFMANN-LA ROCHE, INC. 2003-03-04 US disclosed